[go: up one dir, main page]

DK3134130T3 - Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier - Google Patents

Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier Download PDF

Info

Publication number
DK3134130T3
DK3134130T3 DK15783357.5T DK15783357T DK3134130T3 DK 3134130 T3 DK3134130 T3 DK 3134130T3 DK 15783357 T DK15783357 T DK 15783357T DK 3134130 T3 DK3134130 T3 DK 3134130T3
Authority
DK
Denmark
Prior art keywords
procedures
compositions
treating hemoglobinopathy
hemoglobinopathy
treating
Prior art date
Application number
DK15783357.5T
Other languages
English (en)
Inventor
Michael Milsom
David A Williams
Richard Gregory
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of DK3134130T3 publication Critical patent/DK3134130T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK15783357.5T 2014-04-25 2015-04-24 Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier DK3134130T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461984247P 2014-04-25 2014-04-25
US201462066783P 2014-10-21 2014-10-21
PCT/US2015/027527 WO2015164750A2 (en) 2014-04-25 2015-04-24 Compositions and methods to treating hemoglobinopathies

Publications (1)

Publication Number Publication Date
DK3134130T3 true DK3134130T3 (da) 2019-08-26

Family

ID=54333430

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15783357.5T DK3134130T3 (da) 2014-04-25 2015-04-24 Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier

Country Status (17)

Country Link
US (4) US10287588B2 (da)
EP (2) EP3598984B1 (da)
JP (2) JP6514717B2 (da)
KR (1) KR102390629B1 (da)
CN (2) CN112852812A (da)
AU (1) AU2015249381B2 (da)
BR (1) BR112016024565A2 (da)
CA (1) CA2946309C (da)
DK (1) DK3134130T3 (da)
ES (1) ES2744186T3 (da)
IL (1) IL248469B (da)
MX (1) MX2016013832A (da)
RU (1) RU2707540C2 (da)
SA (1) SA516380143B1 (da)
SG (2) SG11201608482UA (da)
WO (1) WO2015164750A2 (da)
ZA (1) ZA201607540B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102240555B1 (ko) 2012-11-27 2021-04-16 칠드런'즈 메디컬 센터 코포레이션 태아 헤모글로빈 재유도를 위한 bcl11a 원위 조절 요소의 표적화
US10287588B2 (en) 2014-04-25 2019-05-14 The Childrens's Medical Center Corporation Compositions and methods to treating hemoglobinopathies
US11572543B2 (en) 2015-05-08 2023-02-07 The Children's Medical Center. Corporation Targeting BCL11A enhancer functional regions for fetal hemoglobin reinduction
MY192848A (en) * 2015-12-28 2022-09-12 Intellia Therapeutics Inc Compositions and methods for the treatment of hemoglobinopathies
CN117757794A (zh) * 2016-03-07 2024-03-26 美国政府(由卫生和人类服务部的部长所代表) 微小rna及其使用方法
EP3526319A4 (en) 2016-10-14 2020-07-29 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS OF THE CENTRAL NERVOUS SYSTEM
CN110913872B (zh) 2017-01-17 2023-08-04 儿童医疗中心有限公司 治疗溶酶体贮积疾病及病症的组合物和方法
WO2018136434A1 (en) 2017-01-17 2018-07-26 Children's Medical Center Corporation Compositions and methods for diagnosing and treating peroxisomal diseases
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
US11261441B2 (en) * 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
BR112019020322A2 (pt) * 2017-03-29 2020-04-28 Bluebird Bio Inc vetores e composições para o tratamento de hemoglobinopatias
US11788087B2 (en) 2017-05-25 2023-10-17 The Children's Medical Center Corporation BCL11A guide delivery
CN111108207A (zh) * 2017-06-02 2020-05-05 国家健康与医学研究院 用于遗传障碍的基因疗法的基因组编辑手段和结合病毒载体的基因疗法
US10648728B2 (en) 2017-09-29 2020-05-12 Nxp Usa, Inc. Multifunctional radio frequency systems and methods for UV sterilization, air purification, and defrost operations
CN109722414A (zh) * 2017-10-27 2019-05-07 博雅辑因（北京）生物科技有限公司 一种高效制备成熟红细胞的方法以及用于制备成熟红细胞的培养基
WO2019113149A1 (en) * 2017-12-05 2019-06-13 Crispr Therapeutics Ag Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
WO2019213013A1 (en) * 2018-05-02 2019-11-07 The Children's Medical Center Corporation Improved bcl11a micrornas for treating hemoglobinopathies
WO2020193434A1 (en) * 2019-03-22 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Bifunctional vectors allowing bcl11a silencing and expression of an anti-sickling hbb and uses thereof for gene therapy of b- hemoglobinopathies
WO2021067613A1 (en) * 2019-10-01 2021-04-08 Children's Medical Center Corporation Compositions and methods for treating amyotrophic lateral sclerosis
BR112022019889A2 (pt) 2020-04-02 2023-03-07 Mirecule Inc Inibição direcionada com o uso de oligonucleotídeos modificados geneticamente
WO2022266366A1 (en) * 2021-06-16 2022-12-22 Duke University Compositions and methods for the prevention and treatment of hemoglobinopathies
CN114990164B (zh) * 2022-06-16 2023-12-05 北京大学 中介体复合物亚基抑制剂及其应用
WO2025024334A1 (en) 2023-07-21 2025-01-30 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
AU671450B2 (en) 1992-03-20 1996-08-29 Baylor College Of Medicine A DNA transporter system and method of use
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5928638A (en) 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US8101349B2 (en) * 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
EP1076715B1 (en) 1998-05-13 2007-07-18 Genetix Pharmaceuticals Inc. Lentiviral packaging cells
ATE373724T2 (de) 2000-12-01 2007-10-15 Max Planck Gesellschaft Kleine rns moleküle, die rns-interferenz vermitteln
PT2284266E (pt) 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Siarn contra tp53
ATE474460T1 (de) 2002-12-13 2010-08-15 Genetix Pharmaceuticals Inc Therapeutische retrovirus-vektoren für gentherapie
JPWO2005116204A1 (ja) 2004-05-11 2008-06-19 株式会社アルファジェン Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
EP2471956A1 (en) * 2006-01-05 2012-07-04 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
US20080051431A1 (en) 2006-05-26 2008-02-28 Dominique Verhelle Methods and compositions using immunomodulatory compounds in combination therapy
JP5271901B2 (ja) 2007-06-11 2013-08-21 タカラバイオ株式会社 特異的遺伝子発現方法
GB0713183D0 (en) 2007-07-06 2007-08-15 King S College London Method
WO2010030963A2 (en) * 2008-09-15 2010-03-18 Children's Medical Center Corporation Modulation of bcl11a for treatment of hemoglobinopathies
US20110294114A1 (en) 2009-12-04 2011-12-01 Cincinnati Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
MA33899B1 (fr) 2009-12-08 2013-01-02 Hemaquest Pharmaceuticals Inc Procedes et regimes a faible dose pour des troubles des globules rouges
PT2561078T (pt) 2010-04-23 2018-12-03 Cold Spring Harbor Laboratory Sharn com uma conceção estrutural inovadora
GB201012420D0 (en) * 2010-07-23 2010-09-08 Univ Erasmus Medical Ct Foetal heamoglobin inhibitor
WO2012073047A2 (en) 2010-12-03 2012-06-07 Genome Research Limited Compositions and methods
WO2012079046A2 (en) * 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
TR201819015T4 (tr) 2011-06-10 2019-01-21 Bluebird Bio Inc Adrenolökodi̇strofi̇ ve adrenomi̇yelonöropati̇ i̇çi̇n gen terapi̇ vektörleri̇
ES2632444T5 (es) 2011-09-30 2022-03-02 Bluebird Bio Inc Compuestos que mejoran la transducción viral
RU2018109507A (ru) 2012-02-24 2019-02-28 Фред Хатчинсон Кэнсер Рисерч Сентер Композиции и способы лечения гемоглобинопатии
BR112014028631A2 (pt) 2012-05-16 2017-10-17 Rana Therapeutics Inc composições e métodos para modulação da expressão da família de genes da hemoglobina
US20160046961A1 (en) 2012-05-25 2016-02-18 Emmanuelle Charpentier Methods and Compositions for RNA-Directed Target DNA Modification and For RNA-Directed Modulation of Transcription
KR102240555B1 (ko) 2012-11-27 2021-04-16 칠드런'즈 메디컬 센터 코포레이션 태아 헤모글로빈 재유도를 위한 bcl11a 원위 조절 요소의 표적화
RU2701850C2 (ru) 2012-12-12 2019-10-01 Те Брод Инститьют, Инк. Конструирование систем, способы и оптимизированные направляющие композиции для манипуляции с последовательностями
WO2014093965A1 (en) 2012-12-14 2014-06-19 Case Western Reserve University Genomic rna packaging enhancer element
AU2014265331B2 (en) 2013-05-15 2019-12-05 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
SI3492593T1 (sl) 2013-11-13 2022-03-31 Children's Medical Center Corporation Reguliranje izražanja genov s posredovanjem nukleaze
EP3981876A1 (en) 2014-03-26 2022-04-13 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
US20170049819A1 (en) 2014-04-25 2017-02-23 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
US10287588B2 (en) 2014-04-25 2019-05-14 The Childrens's Medical Center Corporation Compositions and methods to treating hemoglobinopathies
MX2016013964A (es) 2014-04-25 2017-04-06 Bluebird Bio Inc Receptores de antigenos quimericos del promotor mnd.
EP3160980B1 (en) 2014-05-28 2020-05-20 The Regents of the University of California HYBRID tRNA/pre-miRNA MOLECULES AND METHODS OF USE
HRP20211648T1 (hr) 2014-12-12 2022-02-04 2Seventy Bio, Inc. Kimerni receptori antigena bcma
WO2016182893A1 (en) 2015-05-08 2016-11-17 Teh Broad Institute Inc. Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
EP3294879A4 (en) 2015-05-14 2019-02-20 University of Southern California OPTIMIZED GENETIZATION WITH A RECOMBINANT ENDONUCLEASE SYSTEM
JP6980659B2 (ja) 2015-08-31 2021-12-15 ヘリックスミス カンパニー， リミテッド 抗シアリルｔｎキメラ抗原受容体
GB201522243D0 (en) 2015-12-16 2016-01-27 Ucl Business Plc Treatment
CN108713059A (zh) 2016-02-12 2018-10-26 蓝鸟生物公司 Vcn增强子组合物和其使用方法
US20190093128A1 (en) 2016-03-31 2019-03-28 The Regents Of The University Of California Methods for genome editing in zygotes
US11788087B2 (en) 2017-05-25 2023-10-17 The Children's Medical Center Corporation BCL11A guide delivery

Also Published As

Publication number Publication date
AU2015249381B2 (en) 2020-04-30
EP3134130A2 (en) 2017-03-01
EP3134130A4 (en) 2018-04-04
NZ726792A (en) 2020-09-25
CA2946309A1 (en) 2015-10-29
SG11201608482UA (en) 2016-11-29
RU2016145964A (ru) 2018-05-25
CN106794260A (zh) 2017-05-31
BR112016024565A2 (pt) 2018-01-23
JP2019129846A (ja) 2019-08-08
RU2707540C2 (ru) 2019-11-27
JP6713073B2 (ja) 2020-06-24
AU2015249381A1 (en) 2016-11-10
MX2016013832A (es) 2017-03-09
KR20170005025A (ko) 2017-01-11
JP2017513505A (ja) 2017-06-01
US11124794B2 (en) 2021-09-21
US20220056453A1 (en) 2022-02-24
US11739329B2 (en) 2023-08-29
JP6514717B2 (ja) 2019-05-15
WO2015164750A3 (en) 2015-12-17
AU2015249381A2 (en) 2018-03-29
ZA201607540B (en) 2019-04-24
US20170218372A1 (en) 2017-08-03
EP3598984A1 (en) 2020-01-29
CN112852812A (zh) 2021-05-28
EP3598984B1 (en) 2024-04-10
US20200370048A1 (en) 2020-11-26
CN106794260B (zh) 2021-02-23
US10287588B2 (en) 2019-05-14
SA516380143B1 (ar) 2020-05-14
RU2016145964A3 (da) 2019-04-23
IL248469B (en) 2020-04-30
US10662429B2 (en) 2020-05-26
EP3134130B1 (en) 2019-06-12
SG10201809290SA (en) 2019-01-30
WO2015164750A2 (en) 2015-10-29
ES2744186T3 (es) 2020-02-24
IL248469A0 (en) 2016-12-29
KR102390629B1 (ko) 2022-04-26
US20190316136A1 (en) 2019-10-17
CA2946309C (en) 2021-11-09

Similar Documents

Publication Publication Date Title
DK3134130T3 (da) Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
HK1257295A1 (zh) 用於免疫腫瘤學的組合物和方法
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3137605T3 (da) Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3368541T3 (da) Sammensætninger og metoder til inhibiering af arginaseaktivitet
DK3386534T3 (da) Sammensætninger og fremgangsmåder til internalisering af enzymer
DK3125927T3 (da) Fremgangsmåder og sammensætninger til immunmodulering
DK3245225T3 (da) Sammensætninger og fremgangsmåder til behandling og detektering af cancere
DK3092256T3 (da) Forbindelser og sammensætninger til immunterapi
DK3206493T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3206497T3 (da) Sammensætninger og fremgangsmåder til behandling af meibomsk kirtel-dysfunktion
DK3888658T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3110988T3 (da) Metoder til behandling af lithiumholdige materialer
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3277270T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK2924093T3 (da) Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse
DK3277771T3 (da) SAMMENSÆTNING OG FREMGANGSMÅDE til INHIBERING AF SULFIDAFLEJRINGER
DK2994533T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3102232T3 (da) Fremgangsmåder og sammensætninger til behandling af abnorm cellevækst